A pilot trial of the daily intraperitoneal administration of recombinant interleukin-2 Academic Article uri icon


MeSH Major

  • Carcinoma
  • Clinical Trials as Topic
  • Neoadjuvant Therapy
  • Ovarian Neoplasms


  • In an effort to develop a rational and practical intraperitoneal (i.p.) recombinant interleukin-2 (rIL-2) program that could be explored in future studies of combination i.p. biological therapy, a pilot trial of single-agent rIL-2 delivered i.p. as a single daily dose on a 5-times-weekly schedule was initiated. With a daily x 5 dose of 8 x 105 units/m2 rIL-2 (Ro 23-6019) only minimal systemic and local toxicity was encountered. This dose is recommended for future trials of combination i.p. biological therapy employing a daily x 5 schedule.

publication date

  • January 1990



  • Academic Article

Additional Document Info

start page

  • 44

end page

  • 46


  • 3


  • 1